Immunotherapy of Renal and Bladder Cancers
15. Lamm DL, Bluemenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma…
Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas
TLR Ligand/agonist Potential therapeutic agents TLR1 Triacylated lipoproteins, lipoteichoic acid, peptidoglycans PAM3CSK4 [93] BCG TLR2 Endogenous DAMPs (HSP, HMGB1, uric acid, fibronectin, ECM proteins) [5] PAM3CSK4 [94–96] BCG [97] HSP60…
Immunology of Cutaneous Tumors and Immunotherapy for Melanoma
43. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell. 2001;106(3):271–4.PubMed 44. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell…
Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma
Approach of immunotherapy Model Reference Alpha-galactosylceramide-pulsed antigen-presenting cells Human [93] Anti-CD3/CD28 monoclonal antibody Human [94] CSC-based vaccination In vivo, in vitro [89, 95] DNA-Hsp65 (a DNA vaccine) Human [96] Epstein-Barr…
Immunotherapy of Pancreatic Cancer
Antigen Location Expression in tumor Prevalence (%) Description CEA Cell surface (GPI-linked) Overexpressed 30–100 Glycoprotein, normally expressed only on oncofetal tissues. Functions as cell-adhesion molecule. First tumor antigen to be…
Immunology and Immunotherapy of Colorectal Cancer
86. Rao H-L, Chen J-W, Li M, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS One. 2012;7:e30806.PubMedCentralPubMed 87. Algars…
Tumor Immunotherapy of Esophageal and Gastric Cancers
Treatment Disease of EGC No. of enrolled patients Clinical response (CR/PR) Median survival (mos) References Cetuximab + FOLFOX/RT + surgery E, ESCC 41 8/12 17 [43] Cetuximab + cisplatin/docetaxel/RT +…
Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma
Regimen Disease status n ORR CR Survival Reference R-GEM High-grade B-NHL (elderly: 64–78 years) 7 (1 previously untreated) 71 % 29 % PFS:10 m [344] OS:11 m R-GEMOX Aggressive NHL…
Immunopathology and Immunotherapy of Hodgkin Lymphoma
Fig. 7.1 The figure demonstrates the immune environment of HRS cells in HL, as well as the antibodies located on the cell surface which are considered potential targets for immunotherapy…
Immunopathology and Immunotherapy of Myeloid Leukemia
Fig. 5.1 Models of pathogenesis of AML. Three possible scenarios for the development of the LSC are shown. Hematopoietic stem cells (HSC) or myeloid progenitors (MP) or both populations are…
